跳至主要内容
临床试验/NCT00100984
NCT00100984终止4 期

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

Hoffmann-La Roche20 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2004年7月21日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
8
试验地点
20

研究概览

简要总结

The main objective of this study is to compare the safety and efficacy of an enfuvirtide containing regimen to a nucleoside combination regimen. Resistance information will also be collected.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • CD4 cell count greater than 50 cells/mm^3
  • HIV-1 RNA viral load greater than or equal to 5000 copies/mL
  • Patients must be HIV treatment experienced
  • Patients diagnosed with HIV-1 infection

排除标准

  • Female patients must not be able to have children or must be under effective contraceptives
  • Female patients who are pregnant
  • Have taken enfuvirtide and/or T-1249 before
  • Have serious kidney problems
  • Alcohol and/or drug abuse
  • Have had an organ transplant

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验

A 48 Week Study Comparing Treatment With Saquinavir... | 临床试验